NL-OMON35459已完成不适用
Determination of the toxicity of standard dose cetuximab together with concurrent individualised, isotoxic accelerated radiotherapy and cisplatin - vinorelbine for patients with stage III non-small cell lung cancer (NSCLC): a phase I study. - Phase I cetuximab and concurrent radio-chemotherapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Histologically confirmed non-small cell lung cancer
- •- Inoperable stage III (UICC 2002; sixth edition) (no pleural effusion)
- •- WHO performance status 0 or 1
- •- Less than 10% weight loss in the last 6 months
- •- Lung function: FEV1 at least 50% and DLCO at least 50% of the predicted value
- •- No recent severe cardiac disease
- •- Adequate bone marrow function
- •- Adequate renal function
- •- Adequate hepatic function
- •- Life expectancy more than 6 months
- •- Measurable cancer
- •- Willing and able to comply with study prescriptions
- •- 18 years or older
- •- Not pregant or breast feeding
- •- Written informed consent
- •- No previous raditherapy to the chest
排除标准
- •- Not non-small cell lung cancer histology
- •- Mixed pathology
- •- History of prior chest radiotherapy
- •- Recent (<3 months) myocardial infarction
- •- Uncontrolled infectious disease
- •- Less than 18 years old
- •- Inadequate pulmonary function
- •- Other active malignancy
研究者
相似试验
尚未招募
Unknown
Acute reactions and dosimetry associated with old and new adjuvant radiation in carcinoma breastCTRI/2024/07/071736Dr.Harikrishna Suresh
进行中（未招募）
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsEUCTR2011-001292-39-HUInstitut de Recherches Internationales Servier90
进行中（未招募）
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-001292-39-SEInstitut de Recherches Internationales Servier90
进行中（未招募）
1 期
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-001292-39-ESab Servier116
进行中（未招募）
1 期
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years.Paediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 16.0 Level: LLT Classification code 10008908 Term: Chronic heart failure System Organ Class: 100000004849EUCTR2011-001292-39-GBInstitut de Recherches Internationales Servier116